Literature DB >> 27012864

Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis.

Y Gu1,2,3, W Zheng1,2, J Zhang2,3, X Gan3,4, X Ma3,5, Z Meng3,5, T Chen2, X Lu1,2, Z Wu1,2, W Huang3,5, R Xu1,2,3.   

Abstract

Blast crisis (BC) is the final deadly phase of chronic myeloid leukemia (CML), but its molecular basis remains poorly understood. Here, we show that CML BC is regulated by calcium-calmodulin-dependent kinase IIγ (CaMKIIγ). Genetic deletion of CaMKIIγ greatly inhibits disease progression via selectively impairing the self-renewal of leukemia stem cells (LSCs) in mouse models, whereas overexpression of CaMKIIγ has the opposite effects. In human CML, phosphorylated CaMKIIγ abundance is significantly associated with BC. Moreover, CaMKIIγ phosphorylates and reduces the nuclear cyclin-dependent kinase inhibitor p27Kip1, a critical brake that maintains LSC quiescence. These findings suggest that CaMKIIγ might be an important switch for the transition of CML BC and identify a unique mechanism by which CaMKIIγ promotes the self-renewal of LSCs by deceasing nuclear p27Kip1 to wake up dormant LSCs. Therefore, CaMKIIγ may provide a new therapeutic target to treat CML BC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27012864     DOI: 10.1038/leu.2016.53

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

1.  Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation.

Authors:  Jutong Si; Steven J Collins
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

2.  A multicellular basis for the origination of blast crisis in chronic myeloid leukemia.

Authors:  Rainer K Sachs; Kerstin Johnsson; Philip Hahnfeldt; Janet Luo; Allen Chen; Lynn Hlatky
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

3.  Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.

Authors:  S Chu; T McDonald; R Bhatia
Journal:  Leukemia       Date:  2010-03-04       Impact factor: 11.528

4.  Berbamine derivatives: a novel class of compounds for anti-leukemia activity.

Authors:  Jinwen Xie; Ting Ma; Ying Gu; Xuzhao Zhang; Xi Qiu; Lei Zhang; Rongzhen Xu; Yongping Yu
Journal:  Eur J Med Chem       Date:  2009-02-23       Impact factor: 6.514

5.  CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.

Authors:  Ying Gu; Ting Chen; Zhipeng Meng; Yichao Gan; Xiaohua Xu; Guiyu Lou; Hongzhi Li; Xiaoxian Gan; Hong Zhou; Jinfen Tang; Genbo Xu; Liansheng Huang; Xiaohong Zhang; Yongming Fang; Kai Wang; Shu Zheng; Wendong Huang; Rongzhen Xu
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

6.  A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1.

Authors:  Weizhou Zhang; Wei Tan; Xuefeng Wu; Maxim Poustovoitov; Amy Strasner; Wei Li; Nicholas Borcherding; Majid Ghassemian; Michael Karin
Journal:  Cancer Cell       Date:  2013-04-18       Impact factor: 31.743

7.  Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

Authors:  Sarah J Neering; Timothy Bushnell; Selcuk Sozer; John Ashton; Randall M Rossi; Pin-Yi Wang; Deborah R Bell; David Heinrich; Andrea Bottaro; Craig T Jordan
Journal:  Blood       Date:  2007-06-29       Impact factor: 22.113

8.  Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Mhairi Copland; Joseph R Slupsky; Richard E Clark
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

9.  Regulation of myeloid leukaemia by the cell-fate determinant Musashi.

Authors:  Takahiro Ito; Hyog Young Kwon; Bryan Zimdahl; Kendra L Congdon; Jordan Blum; William E Lento; Chen Zhao; Anand Lagoo; Gareth Gerrard; Letizia Foroni; John Goldman; Harriet Goh; Soo-Hyun Kim; Dong-Wook Kim; Charles Chuah; Vivian G Oehler; Jerald P Radich; Craig T Jordan; Tannishtha Reya
Journal:  Nature       Date:  2010-07-18       Impact factor: 49.962

10.  CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

Authors:  Hideki Makishima; Anna M Jankowska; Michael A McDevitt; Christine O'Keefe; Simon Dujardin; Heather Cazzolli; Bartlomiej Przychodzen; Courtney Prince; John Nicoll; Harish Siddaiah; Mohammed Shaik; Hadrian Szpurka; Eric Hsi; Anjali Advani; Ronald Paquette; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-02-23       Impact factor: 25.476

View more
  7 in total

Review 1.  Recent advances in understanding chronic myeloid leukemia: where do we stand?

Authors:  Rahul Kumar; Daniela S Krause
Journal:  Fac Rev       Date:  2021-04-01

2.  Activation of CaMKIIγ potentiates T-cell acute lymphoblastic leukemia leukemogenesis via phosphorylating FOXO3a.

Authors:  Xudong Jiang; Zhaoxing Wu; Xiaoya Lu; Xuzhao Zhang; Qingfeng Yu; Yichao Gan; Bowen Wu; Ying Xu; Weiwei Zheng; Lei Zhang; Fei Xu; An Ma; Xiaoxian Gan; Silvia Huang; Xiaofang Yu; Wendong Huang; Rongzhen Xu
Journal:  Oncotarget       Date:  2017-08-24

3.  WTIP upregulates FOXO3a and induces apoptosis through PUMA in acute myeloid leukemia.

Authors:  Yunqi Zhu; Xiangmin Tong; Ying Wang; Xiaoya Lu
Journal:  Cell Death Dis       Date:  2021-12-20       Impact factor: 8.469

4.  CAMK2G is identified as a novel therapeutic target for myelofibrosis.

Authors:  Masashi Miyauchi; Ken Sasaki; Yuki Kagoya; Kazuki Taoka; Yosuke Masamoto; Sho Yamazaki; Shunya Arai; Hideaki Mizuno; Mineo Kurokawa
Journal:  Blood Adv       Date:  2022-03-08

Review 5.  Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.

Authors:  Elena Arrigoni; Marzia Del Re; Sara Galimberti; Giuliana Restante; Eleonora Rofi; Stefania Crucitta; Claudia Baratè; Mario Petrini; Romano Danesi; Antonello Di Paolo
Journal:  Stem Cells Transl Med       Date:  2018-02-08       Impact factor: 6.940

6.  CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ/ Stat3 axis.

Authors:  Linlin Yang; Bowen Wu; Zhaoxing Wu; Ying Xu; Ping Wang; Mengyuan Li; Rongzhen Xu; Yun Liang
Journal:  Aging (Albany NY)       Date:  2020-07-13       Impact factor: 5.682

Review 7.  Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities.

Authors:  Lukasz Komorowski; Klaudyna Fidyt; Elżbieta Patkowska; Malgorzata Firczuk
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.